Preparation Regimens to Improve Capsule Endoscopy Visualization and Diagnostic Yield
NCT ID: NCT05140057
Last Updated: 2021-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
210 participants
INTERVENTIONAL
2021-12-01
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Currently, the European Society of Gastrointestinal Endoscopy (ESGE) recommends that patients ingest a purgative agent (2L of polyethylene glycol, PEG) and antifoaming agents for SBCE, because it was associated with a better visualization. However, it remains unclear which is the optimal timing for purgative use. Furthermore, the use of a booster agent after capsule ingestion is already performed in colon capsule endoscopy, but less is known about its application in SBCE. Also, it remains to be clarified whether a better visualization results in higher diagnostic yield and impacts patients' outcomes.
Therefore, the global aim of this prospective, randomized, multi-centric study is to determine the optimal timing and preparation for small-bowel capsule endoscopy (regardless of the equipment used), comparing four groups of different preparation protocols:
* Protocol 1) 1L of Moviprep® solution the night before the procedure
* Protocol 2) 1L of Moviprep® solution up to 2h before the procedure
* Protocol 3) 0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum (assessed with real-time viewer)
* Protocol 4) 1L of Moviprep® solution after the capsule had reached the duodenum (assessed using real-time viewer)
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Protocol 1
1L of Moviprep® solution the night before the procedure
Moviprep
Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
Protocol 2
1L of Moviprep® solution up to 2h before the procedure
Moviprep
Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
Protocol 3
0.5L of Moviprep® solution up to 2h before the procedure plus 0.5L of Moviprep® solution after the capsule had reached the duodenum
Moviprep
Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
Protocol 4
1L of Moviprep® solution after the capsule had reached the duodenum
Moviprep
Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moviprep
Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Present OGIB (either occult or overt)
* Agree with study's procedures and have signed the informed consent for the study and SBCE, prior to SBCE procedure
Exclusion Criteria
* Inpatients or bedridden
* History of surgery of the esophagus, stomach, small bowel, or colon
* History of abdominal or pelvic radiation therapy
* Suspected or confirmed stenosis or occlusion
* Suspected or confirmed bowel perforation
* Severe comorbidities, as defined by grade 3 "severe decompensation" in the Adult Comorbidity Evaluation-27 index (ACE-27)
* Pregnant women
* Patients using narcotics or prokinetics in the week before the SBCE
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maria Manuela Estevinho
Medical Doctor, Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastroenterology, Centro Hospitalar Vila Nova de Gaia/Espinho
Vila Nova de Gaia, , Portugal
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Manuela Estevinho
Role: primary
Rolando Pinho
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0001
Identifier Type: -
Identifier Source: org_study_id